Cargando…
Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE(®) system
OBJECTIVES: Cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) are well‐established in research settings, but their use in routine clinical practice remains a largely unexploited potential. Here, we examined the relationship between CSF biomarkers, measured by a fully automated im...
Autores principales: | Nojima, Hisashi, Ito, Satoshi, Kushida, Akira, Abe, Aki, Motsuchi, Wataru, Verbel, David, Vandijck, Manu, Jannes, Geert, Vandenbroucke, Ina, Aoyagi, Katsumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735374/ https://www.ncbi.nlm.nih.gov/pubmed/36321325 http://dx.doi.org/10.1002/acn3.51681 |
Ejemplares similares
-
Alzheimer’s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans: CSF AD biomarkers measured by Lumipulse in Koreans
por: Moon, Sohee, et al.
Publicado: (2021) -
Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer’s disease
por: Leitão, Maria João, et al.
Publicado: (2019) -
Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis
por: Sandelius, Åsa, et al.
Publicado: (2019) -
Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease
por: Wilson, Edward N., et al.
Publicado: (2022) -
Analytical evaluation of the novel Lumipulse G BRAHMS procalcitonin immunoassay
por: Ruzzenente, Orazio, et al.
Publicado: (2016)